With only two months left in the year, it’s time to choose the best stocks to invest in 2022 to make this investment year really count! Biotech stocks have been on top of the top gainers list for months now. So it’s not surprising to find Applied DNA Sciences, Inc. (NASDAQ: APDN) and Immunic, Inc. (Nasdaq: IMUX) making headlines today! In this article we will go over the catalysts of the two stocks and why they can be some of the best investments you can make by the end of 2022. Don’t forget to sign for our 100% free alerts so you never miss a run up!!
#1 BEST STOCKS TO INVEST IN 2022 : APDN
Applied DNA Sciences, Inc. (NASDAQ: APDN) is a leading biotechnology company that focuses on developing and commercializing DNA-based technology solutions. APDN has been gaining investors’ attention and made our list for the best stocks to invest in 2022, thanks to its latest press release that shows the tremendous growth potential of the company in the upcoming year.
Through the press release APDN announced that it received its largest purchase order for one of its leading products- LinearDNA. The purchase is valued above the mid six-figures and is planned to be fulfilled over the current quarter and the next three quarters.
It is worth noting that LinearDNA is produced using an enzymatic manufacturing platform. Which eliminates numerous challenges that are usually found in current plasmid-based DNA manufacturing like bacterial contamination and non-target DNA sequences. In simpler terms, this product will enhance the ability to produce DNA more efficiently and rapidly. On that note, APDN’s CEO – Dr. James A. Hayward – said that
We believe LinearDNA sits at the intersection of two growing life sciences segments that hold the potential to transform human health.
Now comes the million dollar question, why is APDN among the best stocks to hold by the end of the year? With everything we already mentioned in mind, it’s easy to see why investors are bullish on this stock. Also bearing in mind that the largest purchase in the history of the company will be on the move for three quarters of 2023. Therefore the PPS is expected to grow in 2023, speaking of the stock, let’s take a look at some charts!
Following the great news of APDN’s largest sale, the stock witnessed a notable 65% increase and is currently being traded at $2.06. APDN has a newly formed resistance at 2.15 with a primary support around 1.39 and a secondary one near 1.11.
Meanwhile MACD is on a bullish crossover with no signs of another crossover in the near future. Accumulation has been fluctuating throughout the day. Lastly the RSI is standing at 69 indicating that the stock is overbought at the moment. This may not be the best entry point with the stock trading far from its resistance and with the high RSI. However the stock is expected to witness higher run ups in the future. Accordingly, bullish investors can time their entry in the next dip!
#2 BEST STOCKS TO INVEST IN 2022 : IMUX
Another biotech company that could make you thousands or even millions is Immunic, Inc. (Nasdaq: IMUX). As a clinical stage biopharmaceutical company, IMUX works on developing a pipeline of selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases.
The company has been gaining momentum for its entrance into a securities purchase agreement. That resulted in the stock going on a 46% run up today, missed this run up? Never miss another one with our 100% free alerts that will help you find the hottest NASDAQ and NYSE Penny stocks before anyone else!
Just this morning, IMUX announced a purchase agreement with a number of accredited investors to issue and sell over 8.6 thousand shares of its common stock at a price of $4.35 per share. Bearing in mind that this a 10% premium to the closing price on October 7th. Also under the terms of agreement, the investors can purchase up to an aggregate of more than 5 thousand common shares at a purchase price of $4.34 per pre-funded warrant share and an exercise price of $0.01 per common share.
$IMUX popping on PIPE:
Sharecount goes from 31m to 45m, cash to (88m @ 2Q22 – 20m/Q burn + 60m) ~130m end 3Q22, ~110m end of year. Stock popped from 4 to $5 pre-market so 5*45=$220m cap, EV ~$110m, & take whatever signal you want from the timing of the transaction. pic.twitter.com/v485053qlG
— brendan (@brendan_49) October 10, 2022
The financing is expected to be closed by October 12th with gross proceeds reaching approximately $60 million (before expenses). IMUX is planning on using the net proceedings of the financing to fund clinical developments for three of its product candidates.
It is also worth mentioning that with the financing and the current cash on hand, the company expects to cover the entirety of its expenses until Q4 2024. Now let’s take a look at the technical analysis of the stock.
Upon the news the stock’s value increased 56% and is now being traded at $6.37 which now serves as its new resistance. IMUX has a primary support near 4,29 and a secondary support around 3.10.
Accumulation has been drastically increasing indicating that investors are holding on to their stocks. Meanwhile the MACD is on a bullish crossover and the RSI is 88 meaning that the stock is extremely overbought right now.
Ending the year with the right stocks can help you make millions in 2023. APDN and IMUX may be some of the best stocks to invest in 2022. But don’t forget to do your DD and choose the right entries and exits!
As always, good luck to all (except the shorts)!
WHEN VIRAL STOCKS HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no business relationship with any company whose stock is mentioned in this article. Viral Stocks is not an investment advisor and this article does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is our opinion and is meant for informational and educational purposes only and does not provide investment advice. Past performance is not indicative of future performance.